Moreover, since previous experiences with once-weekly glucagon-like peptide-1 receptor agonist dosing have demonstrated a considerable reduction in the risk of nonadherence when compared to once-daily dosing [30], the same advantage is likely to be seen with once-weekly insulin as it did not increase the risk of developing hypoglycemia; however, it was also associated with increased body weight, which may influence the patient's adherence. This evidence concerns the gene GLP1R and Hypoglycemia.